Skip to main content

SYSTEMS-BASED VIEW OF MELANOMA PROGRESSION: TOWARDS NOVEL DIAGNOSTIC (AND THERAPEUTIC) APPLICATIONS

Objective

Worldwide figures show that there were 160,000 incidences of melanoma in 2002, whilst 39,000 died from the disease. These upward trends are worrying, as malignant melanoma is one of the most difficult cancers to treat, due to its ability to spread quickly and its resistance to standard chemotherapeutic agents. In order to counteract this trend, targeted therapies that inhibit melanoma metastasis are required. The aim of SYS-MEL is to identify and validate prognostic and predictive biomarkers for melanoma, and to model the predictive value of these biomarkers in determining the efficacy of melanoma therapies. The central objective is to bring together four European academic institutes and two SMEs to develop 3 prognostic/predictive biomarker assays for melanoma. 3 core areas of interest are epigenetics, signalling pathways in melanoma and systems biological approaches for predicting chemotherapy responses. SYS-MEL will have three main elements: 1) Epigenomic and protein expression analysis of melanoma tissue, to validate an epigenomic signature initially identified in the FP7-funded programme Target-Melanoma; 2) In silico modelling and prediction of patient responses to decarbazine DTIC using both in vitro analysis of apoptotic pathways and a novel systems biology approach, incorporating mathematical systems modelling, quantitative biochemistry and cell biology; 3) Investigating the components of the P-Rex1 pathway that are involved in driving the migration of melanoblast cells, and thus the progression of metastasis, incorporating a computational system tailored to model complex signalling pathways. This approach will enable us to identify prognostic and predictive biomarkers for melanoma, and to develop a powerful computational modeling approach to predict disease progression and patient responses to treatment.

Call for proposal

FP7-PEOPLE-2013-IAPP
See other projects for this call

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Address
Belfield
4 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 427 227,16
Administrative Contact
Donal Doolan (Mr.)

Participants (6)

KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 155 485
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Monique Vanhaeren (Ms.)
ROYAL COLLEGE OF SURGEONS IN IRELAND

Participation ended

Ireland
EU contribution
€ 46 982,93
Address
Saint Stephen's Green 123
2 Dublin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Markus Rehm (Dr.)
BEATSON INSTITUTE FOR CANCER RESEARCH LBG
United Kingdom
EU contribution
€ 128 164,96
Address
Switchback Road Garscube Estate
G61 1BD Bearsden
Activity type
Research Organisations
Administrative Contact
Owen Sansom (Prof.)
ONCOMARK LIMITED
Ireland
EU contribution
€ 737 861,11
Address
172 Rathgar Road Rathgar
Dublin 6 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stephen Penney (Mr.)
PATHOLOGY DIAGNOSTICS LTD

Participation ended

United Kingdom
EU contribution
€ 200 383,48
Address
Cowley Road St John S Innovation
CB4 0WS Cambridge Cambridgeshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Vivian Bolton (Mr.)
UNIVERSITY OF STUTTGART
Germany
EU contribution
€ 117 895,36
Address
Keplerstrasse 7
70174 Stuttgart
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Markus Rehm (Prof.)